Egan R W, Athwahl D, Chou C C, Chapman R W, Emtage S, Jenh C H, Kung T T, Mauser P J, Murgolo N J, Bodmer M W
Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
Mem Inst Oswaldo Cruz. 1997;92 Suppl 2:69-73. doi: 10.1590/s0074-02761997000800011.
Interleukin-5 (IL-5) is a critical cytokine for the maturation of eosinophil precursors to eosinophils in the bone marrow and those eosinophils then accumulated in the lungs during asthma. We have studied anti IL-5 antibodies on allergic responses in mice, guinea pigs and monkeys and are extending this experiment into humans with a humanized antibody. In a monkey model of pulmonary inflammation and airway hyperreactivity, we found that the TRFK-5 antibody blocked both responses for three months following a single does of 0.3 mg/kg, i.v. This antibody also blocked lung eosinophilia in mice by inhibiting release from the bone marrow. To facilitate multiple dosing and to reduce immunogenicity in humans, we prepared Sch 55700, a humanized antibody against IL-5. Sch 55700 was also active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in guinea pigs. Furthermore, as opposed to steroids, Sch 55700 did not cause immunosuppression in guinea pigs. Studies with this antibody in humans will be critical to establishing the therapeutic potential of IL-5 inhibition.
白细胞介素-5(IL-5)是一种关键的细胞因子,对于骨髓中嗜酸性粒细胞前体向嗜酸性粒细胞的成熟至关重要,这些嗜酸性粒细胞随后在哮喘发作时会在肺部积聚。我们已经研究了抗IL-5抗体对小鼠、豚鼠和猴子过敏反应的影响,并正在将这项实验扩展到使用人源化抗体的人体研究中。在肺部炎症和气道高反应性的猴子模型中,我们发现,静脉注射0.3 mg/kg的单次剂量后,TRFK-5抗体在三个月内阻断了这两种反应。该抗体还通过抑制骨髓释放来阻断小鼠肺部的嗜酸性粒细胞增多。为了便于多次给药并降低其在人体中的免疫原性,我们制备了Sch 55700,一种抗IL-5的人源化抗体。Sch 55700对过敏性猴子和小鼠的肺部嗜酸性粒细胞增多也有活性,对豚鼠的肺部嗜酸性粒细胞增多和气道高反应性也有活性。此外,与类固醇不同,Sch 55700在豚鼠中不会引起免疫抑制。使用该抗体进行人体研究对于确定抑制IL-5的治疗潜力至关重要。